Storys zum Thema Medicale

Folgen
Keine Story zum Thema Medicale mehr verpassen.
Filtern
  • 24.01.2019 – 14:01

    Merck Healthcare Germany

    Merck Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors

    Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas - Merck retains the rights to both compounds in all other disease areas, including oncology - Merck retains the rights to utilize and ...

  • 23.01.2019 – 16:02

    Philogen

    Philogen Announces Collaboration With Celgene

    Siena, Italy (ots/PRNewswire) - Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Celgene, to discover and develop a new class of immunomodulatory therapeutics. (Logo: https://mma.prnewswire.com/media/811555/Philogen_Logo.jpg ) "We are extremely pleased to establish a new collaboration with Celgene, a leader in the discovery and development ...

  • 23.01.2019 – 16:01

    Philogen

    Philogen Announces Collaboration

    Siena, Italy (ots/PRNewswire) - Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Novartis to discover and develop a new class of immunomodulatory therapeutics. (Logo: https://mma.prnewswire.com/media/811555/Philogen_Logo.jpg ) "We are extremely pleased to establish a new collaboration with Novartis, a leader in the discovery and development of therapies for cancer patients," commented Dr. ...

  • 23.01.2019 – 16:01

    Philogen

    Philogen Announces Drug Discovery Collaboration With Johnson & Johnson Innovation

    Siena, Italy (ots/PRNewswire) - Philogen S.p.A., a privately-owned biotechnology company, today announced through its wholly-owned Swiss subsidiary, Philochem AG, a collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new small molecule-based therapeutics utilizing Philochem's novel ...

  • 09.01.2019 – 10:01

    Medasense Biometrics Ltd

    Medasense Announces Compatibility with Philips IntelliVue Patient Monitors

    Ramat Gan, Israel (ots/PRNewswire) - Medasense Biometrics Ltd., developer of the physiological pain-response monitoring technology (NOL® -- the Nociception Level Index), now supports Philips IntelliVue Patient Monitors for anesthesia and critical care monitoring. (Photo: https://mma.prnewswire.com/media/805789/Medasense_PMD_200_Monitor.jpg ) Commercially available in ...